CoChat

Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results

Adès, Lionel, Sanz, Miguel A., Chevret, Sylvie, Montesinos, Pau, Chevallier, Patrice, Raffoux, Emmanuel, Vellenga, Edo, Guerci, Agnès, Pigneux, Arnaud, Huguet, Francoise, Rayon, Consuelo, Stoppa, Anne Marie, de la Serna, Javier, Cahn, Jean-Yves, Meyer-Monard, Sandrine, Pabst, Thomas, Thomas, Xavier, de Botton, Stéphane, Parody, Ricardo, Bergua, Juan, Lamy, Thierry, Vekhoff, Anne, Negri, Silvia, Ifrah, Norbert, Dombret, Hervé, Ferrant, Augustin, Bron, Dominique, Degos, Laurent, Fenaux, Pierre · 2008 · Blood
Cited by 158

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

All-trans retinoic acid (ATRA) plus anthracycline chemotherapy is the reference treatment of newly diagnosed acute promyelocytic leukemia (APL), whereas the role of cytosine arabinoside (AraC) remains disputed. We performed a joint analysis of patients younger than 65 years included in Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA) LPA 99 trial, where patients received no AraC in addition to ATRA, high cumulative dose idarubicin, and mitoxantrone, and APL 2000 trial, where patients received AraC in addition to ATRA and lower cumulative dose daunorubicin. In patients with white blood cell (WBC) count less than 10 × 109/L, complete remission (CR) rates were similar, but 3-year cumulative incidence of relapse (CIR) was significantly lower in LPA 99 trial: 4.2% versus 14.3% (P = .03), although 3-year survival was similar in both trials. This suggested that AraC is not required in APL with WBC count less than 10 × 109/L, at least in trials with high-dose anthracycline and maintenance treatment. In patients with WBC of 10 × 109/L or more, however, the CR rate (95.1% vs 83.6% P = .018) and 3-year survival (91.5% vs 80.8%, P = .026) were significantly higher in APL 2000 trial, and there was a trend for lower 3-year CIR (9.9% vs 18.5%, P = .12), suggesting a beneficial role for AraC in those patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2007-07-099978

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 158

Metadata

Authors
Adès, L., Sanz, M. A., Chevret, S., Montesinos, P., Chevallier, P., Raffoux, E., Vellenga, E., Guerci, A., Pigneux, A., Huguet, F., Rayon, C., Stoppa, A. M., de la Serna, J., Cahn, J.-Y., Meyer-Monard, S., Pabst, T., Thomas, X., de Botton, S., Parody, R., Bergua, J., Lamy, T., Vekhoff, A., Negri, S., Ifrah, N., Dombret, H., Ferrant, A., Bron, D., Degos, L., & Fenaux, P.
Venue
Blood
Published
2008-02-01
Volume
111
Issue
3
Pages
1078-1084
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2136772335
Cited by
158
References
3
FWCI
4.43
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. https://app.cochat.ai/papers/10.1182/blood-2007-07-099978
The paper
Adès, L., Sanz, M. A., Chevret, S., Montesinos, P., Chevallier, P., Raffoux, E., Vellenga, E., Guerci, A., Pigneux, A., Huguet, F., Rayon, C., Stoppa, A. M., de la Serna, J., Cahn, J.-Y., Meyer-Monard, S., Pabst, T., Thomas, X., de Botton, S., Parody, R., . . . Fenaux, P. (2008). Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood. https://doi.org/10.1182/blood-2007-07-099978

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.